***The policy and linked clinical guide have been updated to capture exclusion criteria for remdesivir to mirror the SmPC (Summary of Product Characteristics)***
***3 February 2022: Update addition of date of SPS guidance and reference to Liverpool COVID-19 Drug Interaction Checker to footnote in Appendix 2.***
***31 January 2022: Update: correction to wording around exclusion criteria for molnupiravir.***
***27 January 2022: We have updated the Clinical Guide to rectify a broken link to the Remdesivir SmPC on page 3. We have also removed asterisk/footnotes on page 3 of the Clinical Guide and Appendix 1 of the Policy next to “corticosteroids”. No other changes have been made.***
The published policy, providing access to monoclonal antibodies or antivirals as treatment options for non-hospitalised patients at highest risk from COVID-19 infection, has been updated to include additional licensed antiviral treatment options – oral PF-07321332 (may also be known as nirmatrelvir) plus ritonavir (Paxlovid) as a new first-line treatment option, and intravenous remdesivir (Veklury) as a second-line treatment option. Intravenous sotrovimab (Xevudy) remains in the policy as a first-line treatment option. Oral molnupiravir (Lagevrio) remains a third-line option. Positive PCR tests or formally registered positive lateral flow tests may now be considered to meet the eligibility requirement on confirmed COVID infection.
These changes are for implementation from Thursday 10 February 2022.
This targeted NHS deployment for patients at highest risk sits alongside the PANORAMIC trial where a different and broader cohort of patients are able to access novel oral antivirals through a clinical study.